Cengild Medical Berhad, an investment holding company, (0243) Fair Value & Analysis
Healthcare · MY · Market cap 171M MYR
Fair value as of: Jun 24, 2026
Analysis
Cengild Medical Berhad, an investment holding company, (0243) currently trades at 0.2000 MYR, while our model-based Fair Value estimate is 0.2400 MYR — implying the stock looks roughly 20.0% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Cengild Medical Berhad, an investment holding company, operates a medical center in Malaysia. The company offers various care and treatment consultant services for gastrointestinal and liver diseases, morbid obesity, and oncology and urological conditions; general cardiology and gynecology assessment; gastroenterology and hepatology; anesthesiology, general surgery, internal medicine, and radiology; ear, nose and throat; gastrointestinal surgeries, including upper gastrointestinal, hepatobiliary, pancreatic, colorectal surgery, and bariatric surgery; and chemotherapy. It also provides medical management services; nursing services and clinical support services; clinical laboratory and pharmacy; operating theatre, endoscopy, radiology and imaging services; accident and emergency care, and health screenings; and consultant services. Cengild Medical Berhad was founded in 2017 and is based in Kuala Lumpur, Malaysia.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Cengild Medical Berhad, an investment holding company, (0243) undervalued?
What is the fair value of 0243?
What is the quality score of 0243?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.